From a Distance: SGO Annual Meeting 2025 - Ovarian Cancer Highlights

I was unable to attend the SGO Annual meeting this year due to a family commitment but I did follow along on X(Twitter).

To kept on top of the action, I followed SGO Social Media Ambassadors Social Media Ambassadors on X- @RiosDoriaMD , @nicoleflemingmd, @meddles28, and @ShannonWestin and others.

Here are some of their ovarian cancer research posts I found most interesting :

Trop-2 is a cell surface protein expressed by cancer cells 

ADC Antibody Drug Conjugate 

Stomatitis is inflammation of the mucous membranes of the mouth . 

58 patients in the study

Dr Rubinstein presenting novel Trop-2 ADC at 3mg/kg dose led to 80% disease control rate in plat-resistant #ovariancancer. Most common toxicity stomatitis which can be managed with early intervention. #SGOMtg #SGO2025 pic.twitter.com/vBqb7Hus5n

— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025

 

GOG 3066/DENALI 

Azenosertib an enzyme inhibitor that binds to called Wee1 and disrupt cell reproduction. 

Cyclin E1 is a protein is encoded by the CCNE1 gene.

 

#SGOMtg- on the scene with Dr Fiona Simpkins to discuss impact of her work exploring WEE1 inhibition in CCNE1-expressing #ovariancancer #gyncsm #SGO2025 @nicoleflemingmd @RiosDoriaMD @meddles28 pic.twitter.com/jmNi8qk8Cv

— Shannon Westin, MD, MPH, FASCO (@ShannonWestin) March 15, 2025

Exciting data by Dr Simpkins from GOG 3066/DENALI study showing activity of Azenosertib in plat-resistant #ovariancancer stratified by cyclin E1 IHC overexpression. ORR 35% in cyclin E1 biomarker positive! #SGOMtg #SGO2025 pic.twitter.com/mlPRIc6AmM

— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025

 GOG 3044

Afuresertib inhibitor of the serine/threonine protein kinase Akt (protein kinase B) . No significant difference in progression free or overall survival.

 

Dr. Herzog presenting @GOG PROFECTA-II/GOG-3044 trial of paclitaxel +/- afuresertib for platinum resistant ov cancer. Negative trial, but identified targets! @SGO_org @GOG #SGO2025 #SGOMtg pic.twitter.com/ZRz5NbAuPv

— erin medlin (@meddles28) March 15, 2025

Starting day 2 of scientific presentations @SGO_org! Dr Herzog presents data from GOG 3044 showing no benefit adding Afuresertib to weekly Taxol in plat-resistant recurrent #ovariancancer. #SGOMtg #SGO2025 pic.twitter.com/up5P6Zb0SZ

— Nicole D. Fleming MD (@nicoleflemingmd) March 15, 2025

EWOC-1 was a study of three different chemotherapy regimens . Use of carboplatin alone was associated with poorer survival.

Congratulations ⁦@JudeNawlo⁩ on ⁦evaluating post-EWOC practice patterns in elderly cohort #ovarinacancer pts! Pts w single agent carbo had worst outcomes- impt@to use platinum doublet when feasible. ⁦@SGO_org⁩ ⁦@GOG⁩ ⁦@IGCSociety⁩ @gyncsm ⁦ pic.twitter.com/efZNiyyP29

— Bhavana Pothuri (@BPothuri) March 15, 2025

 

 Mirv MIRASOL Study of ocular events.

During the #SGOMtg, Tashanna Myers, MD from Baystate Medical Center (@BaystateHealth) presents results from the phase 3 MIRASOL study, which tested the impact of treatment-emergent ocular events on health-related quality of life in patients with FRα-positive platinum-resistance… pic.twitter.com/UxE92NmdaD

— Moffitt Cancer Center (@MoffittNews) March 17, 2025

RAINFOL-01 study (NCT05579366)  

Rinatabart sesutecan (Rina-S) a novel folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC). The treatment in  heavily pretreated patients with platinum-resistant ovarian cancer  showed activity regardless of folate receptor alpha (FRα) expression level.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @EKLee_MD @DanaFarber @SGO_org #SGOMtg #SGO2025 #gyncsmhttps://t.co/4Fpsbj40Js

— OncLive.com (@OncLive) March 17, 2025

 Low Grade Serous Ovarian Cancer 

Combo of Avutometinib  a Ras-Raf-MEK-ERK signaling inhibitor and Defactinib is small molecule inhibtor of focal adhesion kinase (FAK) for KRAS + recurrent low grade OC.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer @SGO_org #SGO2025 #SGOMtg #ovcahttps://t.co/LnYiBw2Vb4

— OncLive.com (@OncLive) March 17, 2025

Please let me know if I missed anything you felt was important for patients/ survivors. 

 I was happy to see ways that patient advocates, researchers and clinicians were able to   #MultiplyYourImpact ! 

Thank you Dr Fader (@amandanfader)  for your leadership!  I look forward to your vision for the future,  Dr Karen Lu (@karenluMD) !

Dee

Every Day is a Blessing! 

Aspirations for 2025

Wishing you all a Happy and Health 2025. 

It's time once again to put together my list of what I aspire to do in 2025. 

• Let's start off with something that has been on my list since 2014. Yes, Visiting Maine remains on my list. Maybe this year?
• Amber is going to be 15 years old this year. I hope to continue to take her on those long walks.
• I will continue to create art - watercolor in particular.
• Exercise is on my list. I'll continue taking lessons and playing Pickleball and dancing in Jazzercise class.
• As the #gyncsm chat on X/Twitter came to a close I started thinking more about the types of advocacy work I am involved with. My ovarian cancer experience, now twenty years old is valuable on some levels but is out of date in other areas. I have no experience with any of the new treatment options. So some activities - updating this blog with the latest ovarian cancer research news, reviewing cancer research grant applications and being a patient advocate advising clinical trials and mentoring other women diagnosed with ovarian cancer will continue.  Slowly, I will scale back other time commitments. I will finish the terms of my appointments on different committees but I will not accept new positions in 2025.
• I look forward to spending more time with Nick, my children, their spouses, my grandsons and friends.
  

I think my word of the year will be SILENCE. The world is a noisy and busy place. I tend to be on the move a lot. So I'll make an effort to just be quiet - no TV, no social media, - just be. 

Dee 

Every Day is a Blessing!